Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials

References

• Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20(2):207–225.
   Google Scholar
• Gatta G, Capocaccia R, Trama A, et al. The burden of rare cancers in Europe. Adv Exp Med Biol. 2010;686:285–303.
   Google Scholar
• Bogaerts J, Sydes MR, Keat N, et al. Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. Eur J Cancer. 2015;51(3):271–281.
   Google Scholar
• Kurman RJ, Shih Ie M. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–747.
   Google Scholar
• Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23(1):41–44.
   Google Scholar
• Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol. 2011;42(7):918–931.
   Google Scholar
• Singer G, Shih I-M, Truskinovsky A, et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol. 2003;22(1):37–41.
   Google Scholar
• Cirisano FD Jr., Robboy SJ, Dodge RK, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol. 1999;74(3):385–394.
   Google Scholar
• Kandoth, C., Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.
   Google Scholar
• Brany D, Dvorska D, Nachajova M, et al. Malignant tumors of the uterine corpus: molecular background of their origin. Tumour Biol. 2015;36(9):6615–6621.
   Google Scholar
• Santin AD, Bellone S, Gokden M, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002;8(5):1271–1279.
   Google Scholar
• Black JD, English DP, Roque DM, et al. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer. Womens Health (Lond Engl). 2014;10(1):45–57.
   Google Scholar
• Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642–646.
   Google Scholar
• Ray-Coquard I, Pujade-Lauraine E, Ledermann JA. New clinical research strategies for rare gynecologic malignancies. Curr Opin Obstet Gynecol. 2015;27(1):53–57.
   Google Scholar
• Bower M, Fife K, Holden L, et al. Chemotherapy for ovarian germ cell tumours. Eur J Cancer. 1996;32a(4):593–597.
   Google Scholar
• Simone CG, Markham MJ, Dizon DS. Chemotherapy in ovarian germ cell tumors: a systematic review. Gynecol Oncol. 2016;141(3):602–607.
   Google Scholar
• Goulvent T, Ray-Coquard I, Borel S, et al. DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO group study. Histopathology. 2016;68(2):279–285.
   Google Scholar
• Ray-Coquard I, Weber B, Lotz JP, et al. Management of rare ovarian cancers: the experience of the French website “Observatory for rare malignant tumours of the ovaries” by the GINECO group: interim analysis of the first 100 patients. Gynecol Oncol. 2010;119(1):53–59.
   Google Scholar
• Auguste A, Bessière L, Todeschini A-L, et al. Molecular analyses of juvenile granulosa cell tumors bearing AKT1 mutations provide insights into tumor biology and therapeutic leads. Hum Mol Genet. 2015;24(23):6687–6698.
   Google Scholar
• Brown J, Friedlander M, Backes FJ, et al. Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S48–54.
   Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   Google Scholar
• Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14(5):195–208.
   Google Scholar
• Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372–379.
   Google Scholar
• Zaino RJ, Brady MF, Lele SM, et al. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a gynecologic oncology group study. Cancer. 2011;117(3):554–562.
   Google Scholar
• Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14(2):134–140.
   Google Scholar
• Fader AN, Java J, Ueda S, et al. Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol. 2013;122(2 Pt 1):225–232.
   Google Scholar
• Bodurka DC, Deavers MT, Tian C, et al. Reclassification of serous ovarian carcinoma by a 2-tier system: a gynecologic oncology group study. Cancer. 2012;118(12):3087–3094.
   Google Scholar
• Morgan RJ Jr., Armstrong DK, Alvarez RD, et al. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(9):1134–1163.
   Google Scholar
• Lheureux, S., Jonathan A.L., Sarah R., et al. Genomic characterization of long-term responders to olaparib. J Clin Oncol. 2015;33(suppl):abstr 5566.
   Google Scholar
• Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003;21(17):3194–3200.
   Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–861.
   Google Scholar
• Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936.
   Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–2045.
   Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–1308.
   Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–2483.
   Google Scholar
• Plaxe SC. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol. 2008;198(4):459.e1-459.e9; discussion 459.e8-9.
   Google Scholar
• Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28(4):496–504.
   Google Scholar
• Gourley C, Farley J, Provencher DM, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S9–S13.
   Google Scholar
• Morgan RJ Jr., Alvarez RD, Armstrong DK, et al. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 2013;11(10):1199–1209.
   Google Scholar
• Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer. 2001;91(12):2329–2334.
   Google Scholar
• Schmeler KM, Sun CC, Bodurka DC, et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008;108(3):510–514.
   Google Scholar
• Grabowski, J.P., Harter P., Heitz F, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol. 2016;140(3):457–462.
   Google Scholar
• Gershenson DM, Sun CC, Iyer RB, et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012;125(3):661–666.
   Google Scholar
• Matsuzaki S, Yoshino K, Ueda Y, et al. Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives. Cancer Cell Int. 2015;15:117.
   Google Scholar
• Okamoto A, Glasspool RM, Mabuchi S, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S20–S25.
   Google Scholar
• Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88(11):2584–2589.
   Google Scholar
• Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(6):945–952.
   Google Scholar
• Sugiyama T, Okamoto A, Enomoto T, et al. Randomized Phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017/GCIG Trial. J Clin Oncol. 2016;34(24):2881–2887.
   Google Scholar
• Grandi G, Toss A, Cortesi L, et al. The association between endometriomas and ovarian cancer: preventive effect of inhibiting ovulation and menstruation during reproductive life. Biomed Res Int. 2015;2015:1–10.
   Google Scholar
• Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532–1543.
   Google Scholar
• Lu F-I, Gilks CB, Mulligan A-M, et al. Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors. Int J Gynecol Pathol. 2012;31(6):524–531.
   Google Scholar
• Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11(18):6422–6430.
   Google Scholar
• Zubac DP, Bostad L, Kihl B, et al. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol. 2009;182(5):2144–2149.
   Google Scholar
• Disis, M.L., Patel M R., Chin K. M., et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial. ASCO Meet Abstr. 2015;33(15_suppl):5509.
   Google Scholar
• Hoskins PJ, Le N, Gilks B, et al. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J Clin Oncol. 2012;30(14):1656–1662.
   Google Scholar
• Ledermann JA, Luvero D, Shafer A, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S14–S19.
   Google Scholar
• Sato S, Itamochi H, Kigawa J, et al. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci. 2009;100(3):546–551.
   Google Scholar
• Anglesio MS, Kommoss S, Tolcher MC, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013;229(1):111–120.
   Google Scholar
• Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group. J Clin Oncol. 2003;21(2):283–290.
   Google Scholar
• Catasús L, Bussaglia E, Rodrguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol. 2004;35(11):1360–1368.
   Google Scholar
• Helder-Woolderink JM, Blok EA, Vasen HFA, et al. Ovarian cancer in Lynch syndrome; a systematic review. Eur J Cancer. 2016;55:65–73.
   Google Scholar
• Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst. 2003;95(2):113–125.
   Google Scholar
• Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S55–S60.
   Google Scholar
• Rauh-Hain JA, Gonzalez R, Bregar AJ, et al. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: a national Cancer database analysis. Gynecol Oncol. 2016;42(1):38–43.
   Google Scholar
• Amant F, Vloeberghs V, Woestenborghs H, et al. Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecol Oncol. 2003;90(2):372–377.
   Google Scholar
• Rauh-Hain JA, Growdon WB, Rodriguez N, et al. Carcinosarcoma of the ovary: a case-control study. Gynecol Oncol. 2011;121(3):477–481.
   Google Scholar
• Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21(6):1180–1189.
   Google Scholar
• Ray-Coquard I, Brown J, Harter P, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S42–S47.
   Google Scholar
• Jamieson S, Fuller PJ. Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr Rev. 2012;33(1):109–144.
   Google Scholar
• Burton ER, Brady M, Homesley HD, et al. A phase II study of paclitaxel for the treatment of ovarian stromal tumors: an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2016;140(1):48–52.
   Google Scholar
• Brown J, Brady WE, Schink J, et al. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the gynecologic oncology group. Cancer. 2014;120(3):344–351.
   Google Scholar
• van Meurs HS, van Lonkhuijzen LRCW, Limpens J, et al. Hormone therapy in ovarian granulosa cell tumors: a systematic review. Gynecol Oncol. 2014;134(1):196–205.
   Google Scholar
• Caburet, S., Anttonen M., Todeschini AL, et al. Combined comparative genomic hybridization and transcriptomic analyses of ovarian granulosa cell tumors point to novel candidate driver genes. BMC Cancer. 2015;15:251.
   Google Scholar
• Mangili G, Scarfone G, Gadducci A, et al. Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). Gynecol Oncol. 2010;119(1):48–52.
   Google Scholar
• Patterson DM, Murugaesu N, Holden L, et al. A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer. 2008;18(1):43–50.
   Google Scholar
• Dark GG, Bower M, Newlands ES, et al. Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol. 1997;15(2):620–624.
   Google Scholar
• Reddy Ammakkanavar N, Matei D, Abonour R, et al. High-dose chemotherapy for recurrent ovarian germ cell tumors. J Clin Oncol. 2015;33(2):226–227.
   Google Scholar
• Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol. 2013;37(6):874–881.
   Google Scholar
• Hoang LN, McConechy MK, Köbel M, et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol. 2013;37(9):1421–1432.
   Google Scholar
• Han G, Sidhu D, Duggan MA, et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol. 2013;26(12):1594–1604.
   Google Scholar
• Koh W-J, Greer BE, Abu-Rustum NR, et al. Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw. 2014;12(2):248–280.
   Google Scholar
• Sagae S, Susumu N, Viswanathan AN, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S83–S89.
   Google Scholar
• Santin AD, Bellone S, Roman JJ, et al. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet. 2008;102(2):128–131.
   Google Scholar
• Hasegawa K, Nagao S, Yasuda M, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S90–S95.
   Google Scholar
• Han G, Soslow RA, Wethington S, et al. Endometrial carcinomas with clear cells: a study of a heterogeneous group of tumors including interobserver variability, mutation analysis, and immunohistochemistry with HNF-1β. Int J Gynecol Pathol. 2015;34(4):323–333.
   Google Scholar
• Cantrell LA, Blank SV, Duska LR. Uterine carcinosarcoma: a review of the literature. Gynecol Oncol. 2015;137(3):581–588.
   Google Scholar
• Reed, N.S., Mangioni C, Malmström H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European organisation for research and treatment of cancer gynaecological cancer group study (protocol 55874). Eur J Cancer. 2008;44(6):808–818.
   Google Scholar
• Omura, G.A., Major F.J., Blessing J.A., et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52(4):626–632.
   Google Scholar
• Pautier, P., Floquet A, Gladieff L, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma group. Ann Oncol. 2013;24(4):1099–1104.
   Google Scholar
• Wolfson, A.H.,Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007;107(2):177–185.
   Google Scholar
• Sutton, G., Kauderer J, Carson LF, et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2005;96(3):630–634.
   Google Scholar
• De Jong, R.A., Nijman HW, Wijbrandi TF, et al. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol. 2011;24(10):1368–1379.
   Google Scholar
• Growdon, W.B., Roussel BN, Scialabba VL, et al. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol. 2011;121(1):212–217.
   Google Scholar
• McMeekin, D.S., Sill MW, Darcy KM, et al. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2012;127(2):356–361.
   Google Scholar
• Huh, W.K., Sill MW, Darcy KM, et al. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a gynecologic oncology group phase Il trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol. 2010;117(2):248–254.
   Google Scholar
• Campos, S.M., Brady WE, Moxley KM, et al. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2014;133(3):537–541.
   Google Scholar
• Aghajanian, C., Sill MW, Secord AA, et al. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a gynecologic oncology group study. Gynecol Oncol. 2012;126(3):424–427.
   Google Scholar
• D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116(1):131–139.
   Google Scholar
• Hensley, M.L., Barrette BA, Baumann K, et al. Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S61–S66.
   Google Scholar
• Barlin JN, Zhou QC, Leitao MM, et al. Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome. Neoplasia. 2015;17(2):183–189.
   Google Scholar
• Lee C-H, Ou W-B, Mariño-Enriquez A, et al. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A. 2012;109(3):929–934.
   Google Scholar
• Amant F, Floquet A, Friedlander M, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S67–S72.
   Google Scholar
• Pautier P, Nam EJ, Provencher DM, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S73–S77.
   Google Scholar
• van der Graaf WTA, Blay J-Y, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–1886.
   Google Scholar
• Kitchener HC, Denton K, Soldan K, et al. Developing role of HPV in cervical cancer prevention. BMJ. 2013;347:f4781.
   Google Scholar
• Angioli R, Lopez S, Aloisi A, et al. Ten years of HPV vaccines: state of art and controversies. Crit Rev Oncol Hematol. 2016;102:65–72.
   Google Scholar
• Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin Number 131: screening for cervical cancer. Obstet Gynecol. 2012;120(5):1222–1238.
   Google Scholar
• Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol. 2010;116(1):140–146.
   Google Scholar
• Koh W-J, Greer BE, Abu-Rustum NR, et al. Cervical Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015;13(4):395–404; quiz 404.
   Google Scholar
• Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–743.
   Google Scholar
• Castellsagué X, Díaz M, de Sanjosé S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98(5):303–315.
   Google Scholar
• Fujiwara K, Monk B, Devouassoux-Shisheboran M. Adenocarcinoma of the uterine cervix: why is it different? Curr Oncol Rep. 2014;16(12):416.
   Google Scholar
• Fujiwara H, Yokota H, Monk B, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S96–S101.
   Google Scholar
• Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;28(22):3562–3569.
   Google Scholar
• Tang J, Tang Y, Yang J, et al. Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma. Gynecol Oncol. 2012;125(2):297–302.
   Google Scholar
• Kim HS, Sardi JE, Katsumata N, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol. 2013;39(2):115–124.
   Google Scholar
• Kim HS, Kim JY, Park NH, et al. Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer. Gynecol Oncol. 2010;119(2):217–224.
   Google Scholar
• Wright AA, Howitt BE, Myers AP, et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013;119(21):3776–3783.
   Google Scholar
• Beller U, Quinn MA, Benedet JL, et al. Carcinoma of the vulva. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S7–S27.
   Google Scholar
• Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;24(Suppl 3):S3/11-25.
   Google Scholar
• Tomao F, Di Tucci C, Marchetti C, et al. Role of chemotherapy in the management of vulvar carcinoma. Crit Rev Oncol Hematol. 2012;82(1):25–39.
   Google Scholar
• Mahner S, Prieske K, Grimm D, et al. Systemic treatment of vulvar cancer. Expert Rev Anticancer Ther. 2015;15(6):629–637.
   Google Scholar
• Chyle V, Zagars GK, Wheeler JA, et al. Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 1996;35(5):891–905.
   Google Scholar
• Carter JS, Downs LS Jr. Vulvar and vaginal cancer. Obstet Gynecol Clin North Am. 2012;39(2):213–231.
   Google Scholar
• Witkowski L, Goudie C, Ramos P, et al. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecol Oncol. 2016;141(3):454–460.
   Google Scholar
• Reed NS, Pautier P, Åvall-Lundqvist E, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S30–S34.
   Google Scholar
• Witkowski L, Carrot-Zhang J, Albrecht S, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet. 2014;46(5):438–443.
   Google Scholar
• Reed NS, Gomez-Garcia E, Gallardo-Rincon D, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S35–S41.
   Google Scholar
• Satoh T, Takei Y, Treilleux I, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S102–S108.
   Google Scholar
• Zhou J, Yang H-Y, Wu S-G, et al. The local treatment modalities in FIGO stage I-II small-cell carcinoma of the cervix are determined by disease stage and lymph node status. Cancer Med. 2016;5(6):1108–1115.
   Google Scholar
• Hoskins PJ, Wong F, Swenerton KD, et al. Small cell carcinoma of the cervix treated with concurrent radiotherapy, cisplatin, and etoposide. Gynecol Oncol. 1995;56(2):218–225.
   Google Scholar
• Tokunaga H, Nagase S, Yoshinaga K, et al. Small cell carcinoma of the uterine cervix: clinical outcome of concurrent chemoradiotherapy with a multidrug regimen. Tohoku J Exp Med. 2013;229(1):75–81.
   Google Scholar
• Chang TC, Lai CH, Tseng CJ, et al. Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer. 1998;83(4):712–718.
   Google Scholar
• Katahira A, Akahira J, Niikura H, et al. Small cell carcinoma of the endometrium: report of three cases and literature review. Int J Gynecol Cancer. 2004;14(5):1018–1023.
   Google Scholar
• D’Antonio A, Addesso M, Caleo A, et al. Small cell neuroendocrine carcinoma of the endometrium with pulmonary metastasis: a clinicopathologic study of a case and a brief review of the literature. Ann Med Surg (Lond). 2016;5:114–117.
   Google Scholar
• Yan WX, Jia XJ, Chen YB, et al. Primary small cell carcinoma of the vagina with pulmonary metastasis: a case report. Eur J Gynaecol Oncol. 2016;37(1):129–132.
   Google Scholar
• Tamura R, Yokoyama Y, Kabayashi A, et al. A case of small cell carcinoma of the vagina. Rare Tumors. 2013;5(4):e58.
   Google Scholar
• Cliby W, Soisson AP, Berchuck A, et al. Stage I small cell carcinoma of the vulva treated with vulvectomy, lymphadenectomy, and adjuvant chemotherapy. Cancer. 1991;67(9):2415–2417.
   Google Scholar
• Eckert F, Fehm T, Bamberg M, et al. Small cell carcinoma of vulva: curative multimodal treatment in face of resistance to initial standard chemotherapy. Strahlenther Onkol. 2010;186(9):521–524.
   Google Scholar
• Harter P, Gershenson D, Lhomme C, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer. 2014;24(9 Suppl 3):S5–S8.
   Google Scholar
• Glasspool RM, González Martín A, Millan D, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S26–S29.
   Google Scholar
• Friedlander ML, Covens A, Glasspool RM, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S78–S82.
   Google Scholar
• Leitao MM Jr., Cheng X, Hamilton AL, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S117–S122.
   Google Scholar
• Mangili G, Lorusso D, Brown J, et al. Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S109–S116.
   Google Scholar
• Blay J-Y, Coindre J-M, Ducimetière F, et al. The value of research collaborations and consortia in rare cancers. Lancet Oncol. 2016;17(2):e62–e69.
   Google Scholar
• Spreafico, A., Blaise C, Helen M., et al. Genotype matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). ASCO Meet Abstr. 2014;32(15_suppl):5506.
   Google Scholar
• Ray-Coquard I, Ledermann J. International journal of gynecological cancer. Editorial. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S2–S4.
   Google Scholar
• Olson TA, Murray MJ, Rodriguez-Galindo C, et al. Pediatric and adolescent extracranial germ cell tumors: the road to collaboration. J Clin Oncol. 2015;33(27):3018–3028.
   Google Scholar
• Parmar MKB, Barthel FM-S, Sydes M, et al. Speeding up the evaluation of new agents in cancer. JNCI J Natl Cancer Inst. 2008;100(17):1204–1214.
   Google Scholar